Can a drug boost Radiation's power against Slow-Growing lymphoma?
NCT ID NCT01473628
Summary
This study is testing whether adding the drug rituximab to standard radiation therapy works better than radiation alone for people with early-stage, slow-growing follicular lymphoma. Rituximab is an immunotherapy drug that helps the immune system attack cancer cells. The main goal is to see which approach keeps the cancer from coming back for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.